Back to search

University of Crete (UOC)

Μελέτη της αντινεοπλασματικής δράσης των αναστολέων των τυροσινικών κινασών [ZD1839 (Gefitinib) και GW572016 (Lapatinib)] στα κυκλοφορούντα μικρομεταστατικά κύτταρα του αίματος σε ασθενείς με καρκίνο μαστού

Abstract

dc:description

Purpose: To investigate the effect of gefitinib (an anti-EGFR TKI ) and lapatinib (a dual EGFR and HER2 tyrosine kinase inhibitor) on circulating tumor cells (CTCs) in patients with metastatic breast cancer (MBC).Methods: Seventeen patients with MBC with detectable CTCs after the completion of prior treatment received gefitinib 250 mg/day p.o. Twenty-two patients with HER2-positive CTCs despite disease stabilization or response to prior therapy, received lapatinib 1500 mg daily. The patients received gefitinib or lapatinib in monthly cycles, till disease progression or CTC increase. CTC monitoring was performed by immunofluorescent microscopy using cytospins of peripheral blood mononuclear cells (PBMCs) double stained for HER2 or EGFR and cytokeratin. Results a) Patients who received gefitinib: a median reduction of 96.4 and 94.1 % in CTC count was observed in 11 (64.7 %) and 12 (70.6 %) of patients after the first and the second treatment cycles, respectively. Total CTC numbers declined by 73 and 44 % after the first and second treatment cycles, respectively. In nine patients with EGFR(+)/CK(+) CTCs, gefitinib resulted in a reduction of both EGFR(+) and EGFR(−) CTCs, and after the third course, most detected CTCs were EGFR(−). In two patients, with a sustained decrease in CTC numbers, a PFS of 16.0 and 19.0 months was observed and in one of them, it was associated with clinical objective response.b) Patients who received lapatinib: A total of 120 cycles were administered in 22 patients; median age was 62.5 years, 15 (68.2%) patients were post-menopausal and 20 (90.1%) had HER2-negative primary tumors. At the end of the second course, HER2-positive CTC counts decreased in 76.2% of patients; the median number of HER2-positive CTCs/patient also declined significantly (p=0.013), however the decrease was significant only among patients presenting disease stabilization (p=0.018) but not among those with disease progression during lapatinib treatment. No objective responses were observed. All CTC-positive patients harbored EGFR-positive CTCs on progression compared to 62.5% at baseline (p=0.054). The ratio of EGFR-positive CTCs/total CTCs detected in all patients increased from 17.1% at baseline to 37.6% on progression, whereas the mean percentage of HER2-negative CTCs/patient increased from 2.4% to 30.6% (p=0.03).Conclusion:Treatment-resistant CTCs could be eliminated by gefitinib or lapatinib in MBC, and both EGFR and HER2 expressions on CTCs merit further validation as potential biomarkers for specific and effective targeting of CTCs.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kalykaki, Antonia
  • Καλυκάκη, Αντωνία

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/36635

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kalykaki, Antonia; Καλυκάκη, Αντωνία. Μελέτη της αντινεοπλασματικής δράσης των αναστολέων των τυροσινικών κινασών [ZD1839 (Gefitinib) και GW572016 (Lapatinib)] στα κυκλοφορούντα μικρομεταστατικά κύτταρα του αίματος σε ασθενείς με καρκίνο μαστού. University of Crete (UOC), 2015. http://hdl.handle.net/10442/hedi/36635